Fractyl Health, Inc. (GUTS) Stock Analysis & Investment Frameworks
Fractyl Health, Inc. (GUTS) stock analysis on Invetso. Review Fractyl Health, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Fractyl Health, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Fractyl Health, Inc. Key Financial Metrics
- Market Cap: $12.33M
- Revenue: $N/A
- ROE: -1625.88%
- ROIC: -120.27%
- Dividend Yield: N/A
About Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Fractyl Health, Inc. Investment Frameworks
Invetso analyzes Fractyl Health, Inc. (GUTS) across the following frameworks:
- Fractyl Health, Inc. 10Y Growth Potential
- Fractyl Health, Inc. Scenario Analysis
- Fractyl Health, Inc. Risks & Opportunities
- Fractyl Health, Inc. Economic Moat
- Fractyl Health, Inc. Business Model
- Fractyl Health, Inc. Management
- Fractyl Health, Inc. SWOT Analysis
- Fractyl Health, Inc. Porter's 5 Forces
- Fractyl Health, Inc. PESTLE Analysis
- Fractyl Health, Inc. ESG Analysis